Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 144

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 144
---
 $330.4 million from the sale of our preferred stock in private placements. As of September 30, 2024, we had $180.9 million in cash, cash equivalents and marketable securities. Cash Flows The following table sets forth a summary of the net cash flow activity (in thousands):

|                                                                       | 2024 | Nine Months Ended 
 September 30,     |          |   | 2023 |   |         |   | 2023 | Year Ended December 31, |         |   | 2022 |   |         |   |
|:----------------------------------------------------------------------|:-----|:------------------|---------:|:--|:-----|:--|--------:|:--|:-----|:------------------------|--------:|:--|:-----|:--|--------:|:--|
| Net cash used in operating activities                                 |      | $                 |  (41,006 | ) |      | $ | (36,247 | ) |      | $                       | (43,699 | ) |      | $ | (36,068 | ) |
| Net cash (used in) provided by investing activities                   |      |                   | (142,141 | ) |      |   |  20,224 |   |      |                         |  27,352 |   |      |   | (29,263 | ) |
| Net cash provided by financing activities                             |      |                   |  180,375 |   |      |   |      31 |   |      |                         |      31 |   |      |   | 110,855 |   |
| Net (decrease) increase in cash, cash equivalents and restricted cash |      | $                 |   (2,772 | ) |      | $ | (15,992 | ) |      | $                       | (16,316 | ) |      | $ |  45,524 |   |

Operating Activities For the nine months ended September 30, 2024, net cash used in operating activities was $41.0 million primarily due to our net loss of $45.8 million and changes in operating assets and liabilities of $6.2 million, partially offset by $11.0 million of non-cashcharges related to non-cashlicense expense, stock-based compensation, depreciation, non-cashoperating lease expense and amortization of discounts on marketable securities. 104

For the nine months ended September 30